CN1269818C - 内酰胺化合物及其药物用途 - Google Patents

内酰胺化合物及其药物用途 Download PDF

Info

Publication number
CN1269818C
CN1269818C CNB018223559A CN01822355A CN1269818C CN 1269818 C CN1269818 C CN 1269818C CN B018223559 A CNB018223559 A CN B018223559A CN 01822355 A CN01822355 A CN 01822355A CN 1269818 C CN1269818 C CN 1269818C
Authority
CN
China
Prior art keywords
substituted
unsubstituted
group
ring
acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018223559A
Other languages
English (en)
Chinese (zh)
Other versions
CN1487940A (zh
Inventor
饭野幸生
池上孝雄
近藤信雄
松枝裕之
畑中敏宏
平间龙介
增泽阳子
太田史生
山崎晶代
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EA Pharma Co Ltd
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of CN1487940A publication Critical patent/CN1487940A/zh
Application granted granted Critical
Publication of CN1269818C publication Critical patent/CN1269818C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
CNB018223559A 2000-12-01 2001-11-29 内酰胺化合物及其药物用途 Expired - Fee Related CN1269818C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP367175/2000 2000-12-01
JP2000367175 2000-12-01
JP367175/00 2000-12-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200610095903A Division CN100577651C (zh) 2000-12-01 2001-11-29 内酰胺化合物及其药物用途

Publications (2)

Publication Number Publication Date
CN1487940A CN1487940A (zh) 2004-04-07
CN1269818C true CN1269818C (zh) 2006-08-16

Family

ID=18837660

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB018223559A Expired - Fee Related CN1269818C (zh) 2000-12-01 2001-11-29 内酰胺化合物及其药物用途
CN200610095903A Expired - Fee Related CN100577651C (zh) 2000-12-01 2001-11-29 内酰胺化合物及其药物用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200610095903A Expired - Fee Related CN100577651C (zh) 2000-12-01 2001-11-29 内酰胺化合物及其药物用途

Country Status (26)

Country Link
US (3) US7153850B2 (enExample)
EP (1) EP1346993B1 (enExample)
JP (2) JP3826400B2 (enExample)
KR (1) KR100826818B1 (enExample)
CN (2) CN1269818C (enExample)
AT (1) ATE446297T1 (enExample)
AU (3) AU1850202A (enExample)
BG (1) BG107857A (enExample)
BR (1) BR0115852A (enExample)
CA (1) CA2430124C (enExample)
CZ (1) CZ20031520A3 (enExample)
DE (1) DE60140270D1 (enExample)
ES (1) ES2331299T3 (enExample)
HU (1) HUP0400806A3 (enExample)
IL (1) IL156158A0 (enExample)
MX (1) MXPA03004876A (enExample)
NO (1) NO325401B1 (enExample)
NZ (1) NZ526164A (enExample)
PL (1) PL362835A1 (enExample)
RU (1) RU2287530C2 (enExample)
SK (1) SK6582003A3 (enExample)
TW (1) TWI241302B (enExample)
UA (1) UA76969C2 (enExample)
WO (1) WO2002044180A1 (enExample)
YU (1) YU42603A (enExample)
ZA (1) ZA200304100B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2331299T3 (es) * 2000-12-01 2009-12-29 Ajinomoto Co., Inc. Compuestos de lactama y su uso medico.
MXPA05008363A (es) * 2003-02-07 2005-12-06 Ajinomoto Kk Agentes terapeuticos para diabetes.
CA2544310A1 (en) 2003-10-31 2005-05-12 Ajinomoto Co., Inc. New fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof
JPWO2005068467A1 (ja) * 2004-01-14 2007-12-27 味の素株式会社 新規縮環化合物
JP2008515939A (ja) * 2004-10-13 2008-05-15 エフ．ホフマン−ラ ロシュ アーゲー Ｃｄｋ２及び血管形成の阻害剤として、及び乳癌、結腸癌及び前立腺癌の治療に有用な２置換ピラゾロベンゾジアゼピン
NZ563131A (en) * 2005-04-28 2010-09-30 Ajinomoto Kk Tricyclic lactam compound as a hypoglycemic agent
EP2157092A4 (en) 2007-04-11 2011-04-13 Ajinomoto Kk Remedy for diabetes
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008139575A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. 経口投与用製剤
WO2008136394A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の製造方法及びその製造中間体
CN101619041B (zh) * 2008-07-02 2012-07-04 重庆华邦制药股份有限公司 一种二酮基含氮环化合物的合成方法及其中间体
JP2012180282A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
JP2012180283A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
RU2017126027A (ru) * 2014-12-22 2019-01-24 ЕА Фарма Ко., Лтд. Лекарственное средство для лечения расстройств эпителия роговицы
AU2017208970A1 (en) 2016-01-18 2018-08-02 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
WO2020151671A1 (en) * 2019-01-23 2020-07-30 Glycolysis Biomed Co., Ltd Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US189597A (en) * 1877-04-17 Improvement in portable wash-stands
US48847A (en) * 1865-07-18 Improvement in vessels for reception and transportation of night-soil
GB8720414D0 (en) * 1987-08-28 1987-10-07 Roussel Lab Ltd Chemical compounds
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
NZ502448A (en) 1997-07-30 2002-12-20 Wyeth Corp Tricyclic vasopressin agonists and medicaments containing these compounds
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
ES2331299T3 (es) * 2000-12-01 2009-12-29 Ajinomoto Co., Inc. Compuestos de lactama y su uso medico.
MXPA05008363A (es) 2003-02-07 2005-12-06 Ajinomoto Kk Agentes terapeuticos para diabetes.

Also Published As

Publication number Publication date
RU2287530C2 (ru) 2006-11-20
PL362835A1 (en) 2004-11-02
AU2006241377A1 (en) 2006-12-14
US7326701B2 (en) 2008-02-05
US7153850B2 (en) 2006-12-26
YU42603A (sh) 2006-03-03
CA2430124C (en) 2011-01-11
JP2006213732A (ja) 2006-08-17
ZA200304100B (en) 2004-08-22
NO20032439D0 (no) 2003-05-28
US7632830B2 (en) 2009-12-15
US20040048847A1 (en) 2004-03-11
JP3826400B2 (ja) 2006-09-27
ATE446297T1 (de) 2009-11-15
CN100577651C (zh) 2010-01-06
AU2006241377B2 (en) 2009-01-08
US20060189597A1 (en) 2006-08-24
AU2002218502B2 (en) 2006-09-21
BR0115852A (pt) 2003-12-23
IL156158A0 (en) 2003-12-23
EP1346993A1 (en) 2003-09-24
KR100826818B1 (ko) 2008-05-02
CA2430124A1 (en) 2002-06-06
US20080096862A1 (en) 2008-04-24
JPWO2002044180A1 (ja) 2004-04-02
NO20032439L (no) 2003-07-18
SK6582003A3 (en) 2003-09-11
JP4505753B2 (ja) 2010-07-21
MXPA03004876A (es) 2004-01-27
UA76969C2 (en) 2006-10-16
ES2331299T3 (es) 2009-12-29
DE60140270D1 (de) 2009-12-03
CZ20031520A3 (cs) 2003-10-15
EP1346993B1 (en) 2009-10-21
CN1487940A (zh) 2004-04-07
KR20030051893A (ko) 2003-06-25
EP1346993A4 (en) 2005-12-21
AU1850202A (en) 2002-06-11
NZ526164A (en) 2004-09-24
HUP0400806A3 (en) 2007-11-28
HUP0400806A2 (hu) 2004-07-28
CN1911915A (zh) 2007-02-14
NO325401B1 (no) 2008-04-21
WO2002044180A1 (en) 2002-06-06
TWI241302B (en) 2005-10-11
BG107857A (bg) 2004-06-30

Similar Documents

Publication Publication Date Title
CN1269818C (zh) 内酰胺化合物及其药物用途
CN1181817C (zh) 以苯基甲苯醌为有效成分的NF-kB抑制剂
CN1324015C (zh) 吡啶－和嘧啶－衍生物
CN1212861C (zh) 以NF－κB抑制剂为有效成分的心肌炎、扩张型心肌病和心衰的预防或治疗药
CN1681763A (zh) 化合物
CN1161333C (zh) 作为生长激素释放剂的2-羟基吲哚衍生物
CN1684966A (zh) 新的腺嘌呤化合物及其用途
CN1395562A (zh) 含氮的环状化合物及含有该化合物的药物组合物
CN1678578A (zh) 具有抗糖尿病活性的吲哚化合物
CN1946666A (zh) 用于治疗代谢性疾病的化合物、药物组合物和方法
CN1897936A (zh) 环状胍、含有这种化合物的组合物及其使用方法
CN101048402A (zh) 咔唑衍生物、其溶剂合物或其药学上允许的盐
CN1444582A (zh) 杂环化合物,它们的制备和用途
CN1791568A (zh) Hsp90家族蛋白质阻断剂
CN1492852A (zh) 作为fsad的nep抑制剂的n-苯丙基环戊基取代的戊二酰胺衍生物
CN1245405C (zh) 哌嗪衍生物
CN101068781A (zh) 用于阿尔茨海默氏病的化合物
CN1788002A (zh) 作为钠通道阻滞剂的联芳基取代的三唑化合物
CN100347158C (zh) 二环化合物
CN1774244A (zh) 用于治疗代谢紊乱的化合物
CN1886416A (zh) Comt抑制剂
CN1292697A (zh) 抗病毒化合物
CN1791575A (zh) 氰基氟代吡咯烷
CN1922156A (zh) 作为钠通道阻断剂的取代的三唑
CN101061092A (zh) 烟酸受体激动剂、含有这样化合物的组合物和治疗方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160727

Address after: Tokyo, Japan, Japan

Patentee after: EA pharmaceutical KK

Address before: All of central Tokyo Japan

Patentee before: Ajinomoto K. K.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060816

Termination date: 20181129

CF01 Termination of patent right due to non-payment of annual fee